What are skin substitutes?
A skin substitute is a product that is engineered from human, animal or synthetic materials and is used to treat chronic non-healing wounds such as diabetic ulcers and venous leg ulcers.
Skin substitute codes range from Q4100-Q4353 and new codes Q4418-Q4440 have been added to the list as of April 1, 2026.
History and Changes
In October 2025, the Centers for Medicare and Medicaid [CMS] announced they would be updating their Local Coverage Determinations [LCDs] for certain skin substitutes that targeted diabetic foot ulcers and venous leg ulcers that would limit the types of products used.
On October 31, 2025, the CMS press release stated “Medicare spending on wound care products known as “skin substitutes” has had unprecedented growth, rising from $256 million in 2019 to over $10 billion in 2024, according to Medicare Part B claims data. This dramatic spending increase is largely attributed to abusive pricing practices in the sector, including the use of products with limited evidence of clinical value. Current prices can reach more than $2,000 per square centimeter.
In 2025, the CMS Fraud Defense Operations Center (FDOC) stopped nearly $185 million in improper payments to suspect providers billing of skin substitutes. In one notable case identified in September 2025, the FDOC stopped more than $4.3 million in suspected improper payments submitted by a medical group practice. Virtually all the $4.3 million was for wound care services purportedly provided to a single beneficiary who lacked evidence of prior wound treatment.
The CMS currently treats skin substitutes as biologicals for the purposes of Medicare payment. In the CY 2026 Physician Fee Schedule [MPFS] final rule, the CMS will pay for skin substitutes under the MPFS as incident-to supplies, a change expected to reduce Medicare spending on these products by nearly 90% without compromising patient access or quality of care. We estimate this action will reduce gross fee-for-service program spending for skin substitute services by $19.6 billion in 2026, while incentivizing the use of products with the most clinical evidence of success.”
On December 29, 2025, CMS decided to withdraw the LCD update but still decided to move forward with the new payment methodology. Beginning January 2026, CMS updated the methodology from Average Sale Price [ASP] to a standard or flat rate of $127.28 per cm2 under the MPFS in a non-facility setting. The CMS also finalized an updated payment policy in the hospital outpatient setting, which can be found in the CY 2026 OPPS/Ambulatory Surgical Center [ASC]Rule. The rule states it will unpackage skin substitutes products from application services, identified by procedure code range 15271 to 15278, and establish new APCs based on product characteristics. The CMS also finalized to align skin substitute categorization for payment purposes to FDA regulatory status for 361 Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/P) and device types: Pre-Market Approvals (PMAs) and 510(k)s.
How can Codoxo’s Fraud Scope platform assist health plans?
In April 2025 we published an AI Alert titled “Peeling Back the Layer of Skin Substitutes” that focused on skin substitutes and the fraud schemes surrounding them. The same schemes still hold true today.
Fraud Scope assists our partners with identifying providers abusing skin substitute billing through our pattern-based detectors, such as Suspicious Trends and Outlier Abuse. These detectors identify the shift in utilization based on units billed per day, high patient volumes, and a provider’s reliance on procedure codes for a high percentage of their revenue. The Fraud Scope Dashboard offers our partners the “New Utilization of Codes” widget, which documents a provider billing a code that is new to their claim’s history.
Fraud Scope’s query toolkits allow users to tailor specific reports to look for spikes and trends as well as the supporting line level claims data. Our partners can quickly summarize and identify the providers are using the skin substitute codes, frequency of billing, how the prices changed over time per provider, billing patterns, payment anomalies, and utilization outliers against their peers. AI Query, our Gen AI query tool, can assist our partners with quickly identifying increases with units of service for skin substitutes as well as identify shifting utilization changes to different codes by the same provider.
References / New Articles:
Centers of Medicare and Medicaid Services, Newsroom CMS Modernizes Payment Accuracy and Significantly Cuts Spending Waste
Centers for Medicare and Medicaid Services, CY 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Calendar Year 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center Final Rule (CMS-1834-FC)
Centers for Medicare and Medicaid Services, Newsroom Final Local Coverage Determination (LCSs) for Certain Skin Substitutes Withdrawn